Marcus Koch

List of Publications by Year
in descending order

99 papers	4,252 citations	109264 35 h-index	118793 62 g-index
104 all docs	104 docs citations	104 times ranked	5932 citing authors

#	Article	IF	Citations
1	Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurology, 2013, 13, 128.	0.8	392
2	Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. Journal of the Neurological Sciences, 2008, 267, 3-16.	0.3	205
3	The natural history of secondary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1039-1043.	0.9	191
4	Tremor in multiple sclerosis. Journal of Neurology, 2007, 254, 133-145.	1.8	180
5	Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review. Neuroepidemiology, 2013, 40, 195-210.	1.1	169
6	An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. Nature Communications, 2016, 7, 11312.	5.8	167
7	The natural history of primary progressive multiple sclerosis. Neurology, 2009, 73, 1996-2002.	1.5	156
8	Epigenetic changes in patients with multiple sclerosis. Nature Reviews Neurology, 2013, 9, 35-43.	4.9	119
9	Seizures in multiple sclerosis. Epilepsia, 2008, 49, 948-953.	2.6	104
10	Hypoperfusion of the Cerebral White Matter in Multiple Sclerosis: Possible Mechanisms and Pathophysiological Significance. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1645-1651.	2.4	101
11	Moderate hyperglycaemia is associated with favourable outcome in acute lacunar stroke. Brain, 2007, 130, 1626-1630.	3.7	100
12	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 2007, 68, 1163-1164.	1.5	94
13	Plasma homocysteine levels in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 189-192.	0.9	89
14	Therapeutic Potential of Fluoxetine in Neurological Disorders. CNS Neuroscience and Therapeutics, 2008, 14, 153-164.	1.9	89
15	Progression in multiple sclerosis: Further evidence of an age dependent process. Journal of the Neurological Sciences, 2007, 255, 35-41.	0.3	83
16	Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology, 2010, 74, 1822-1826.	1.5	82
17	Cigarette smoking and progression in multiple sclerosis. Neurology, 2007, 69, 1515-1520.	1.5	81
18	Validity of four screening scales for major depression in MS. Multiple Sclerosis Journal, 2015, 21, 1064-1071.	1.4	77

#	Article	IF	Citations
19	Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. Journal of Neurology, 2006, 253, 483-487.	1.8	74
20	Safety of Antiplatelet Therapy Prior to Intravenous Thrombolysis in Acute Ischemic Stroke. Archives of Neurology, 2008, 65, 607-11.	4.9	67
21	Depression in multiple sclerosis: A long-term longitudinal study. Multiple Sclerosis Journal, 2015, 21, 76-82.	1.4	66
22	Parity and secondary progression in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 676-678.	0.9	63
23	Plasma lipid peroxidation and progression of disability in multiple sclerosis. European Journal of Neurology, 2007, 14, 529-533.	1.7	59
24	Environmental factors and their regulation of immunity in multiple sclerosis. Journal of the Neurological Sciences, 2013, 324, 10-16.	0.3	59
25	Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. Journal of Neurology, 2008, 255, 875-880.	1.8	58
26	Pharmacologic treatment of depression in multiple sclerosis. The Cochrane Library, 2011, , CD007295.	1.5	53
27	Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic. Nature Communications, 2017, 8, 1990.	5.8	50
28	Fatigue, depression and progression in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 815-822.	1.4	47
29	Reduced Creatine Kinase B Activity in Multiple Sclerosis Normal Appearing White Matter. PLoS ONE, 2010, 5, e10811.	1.1	47
30	Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis. Journal of the Neurological Sciences, 2015, 358, 131-137.	0.3	45
31	Quetiapine Fumarate for the Treatment of Multiple Sclerosis: Focus on Myelin Repair. CNS Neuroscience and Therapeutics, 2013, 19, 737-744.	1.9	44
32	Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis. European Journal of Neurology, 2007, 14, 797-800.	1.7	40
33	Treatment trials in progressive MSâ€”current challenges and future directions. Nature Reviews Neurology, 2013, 9, 496-503.	4.9	40
34	Uric acid in multiple sclerosis. Neurological Research, 2006, 28, 316-319.	0.6	38
35	Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis. Trends in Molecular Medicine, 2013, 19, 23-30.	3.5	38
36	Cerebral white matter blood flow and energy metabolism in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1282-1289.	1.4	37

#	Article	IF	Citations
37	Fatigue, depression and disability accumulation in multiple sclerosis: a crossâ€sectional study. European Journal of Neurology, 2009, 16, 348-352.	1.7	33
38	Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?. Multiple Sclerosis Journal, 2018, 24, 1543-1556.	1.4	33
39	Lack of association between serum uric acid levels and outcome in acute ischemic stroke. Journal of the Neurological Sciences, 2012, 319, 51-55.	0.3	32
40	MS incidence and prevalence in Africa, Asia, Australia and New Zealand: A systematic review. Multiple Sclerosis and Related Disorders, 2014, 3, 48-60.	0.9	32
41	Factors associated with the risk of secondary progression in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 799-803.	1.4	30
42	Hemorrhagic encephalopathy associated with COVID-19. Journal of Neuroimmunology, 2020, 346, 577326.	1.1	29
43	Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. The Cochrane Library, 2009, , CD006453.	1.5	26
44	T2 lesions and rate of progression of disability in multiple sclerosis. European Journal of Neurology, 2010, 17, 1471-1475.	1.7	26
45	Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 537-540.	0.9	25
46	Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study. PLoS ONE, 2015, 10, e0123824.	1.1	25
47	Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 96, e111-e120.	1.5	24
48	Hydroxychloroquine for Primary Progressive Multiple Sclerosis. Annals of Neurology, 2021, 90, 940-948.	2.8	23
49	Does smoking influence outcome after intravenous thrombolysis for acute ischaemic stroke?. European Journal of Neurology, 2009, 16, 819-822.	1.7	22
50	Transmission ofChlamydia pneumoniaeinfection from blood monocytes to vascular cells in a novel transendothelial migration model. FEMS Microbiology Letters, 2005, 242, 203-208.	0.7	20
51	Plasma S100Î² and NSE levels and progression in multiple sclerosis. Journal of the Neurological Sciences, 2007, 252, 154-158.	0.3	20
52	Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 159-165.	1.4	20
53	The natural history of early versus late disability accumulation in primary progressive MS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 615-621.	0.9	20
54	Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets. Multiple Sclerosis Journal, 2020, 26, 1540-1549.	1.4	20

#	Article	IF	Citations
55	Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent. Journal of Neurology, 2020, 267, 2619-2624.	1.8	20
56	Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. Neurology, 2021, 97, e1560-e1570.	1.5	19
57	Hand dexterity and direct disease related cost in multiple sclerosis. Journal of the Neurological Sciences, 2014, 341, 51-54.	0.3	18
58	Erythrocyte membrane fatty acids in benign and progressive forms of multiple sclerosis. Journal of the Neurological Sciences, 2006, 244, 123-126.	0.3	17
59	Comparative utility of disability progression measures in PPMS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e358.	3.1	17
60	The promise of futility trials in neurological diseases. Nature Reviews Neurology, 2015, 11, 300-305.	4.9	16
61	Global transcriptome profiling of mild relapsingâ€remitting versus primary progressive multiple sclerosis. European Journal of Neurology, 2018, 25, 651-658.	1.7	15
62	Timing of birth and disease progression in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 793-798.	1.4	14
63	Disease onset in familial and sporadic primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 694-700.	1.4	14
64	Performance on Paced Auditory Serial Addition Test and cerebral blood flow in multiple sclerosis. Acta Neurologica Scandinavica, 2013, 128, n/a-n/a.	1.0	13
65	Serum NSE level and disability progression in multiple sclerosis. Journal of the Neurological Sciences, 2015, 350, 46-50.	0.3	13
66	Jerking & confused: Leucine-rich glioma inactivated 1 receptor encephalitis. Journal of Neuroimmunology, 2015, 289, 84-86.	1.1	13
67	Aging-Exacerbated Acute Axon and Myelin Injury Is Associated with Microglia-Derived Reactive Oxygen Species and Is Alleviated by the Generic Medication Indapamide. Journal of Neuroscience, 2020, 40, 8587-8600.	1.7	13
68	Repurposing Domperidone in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 96, e2313-e2322.	1.5	13
69	Progression in familial and nonfamilial MS. Multiple Sclerosis Journal, 2008, 14, 300-306.	1.4	12
70	Subacute sclerosing panencephalitis in pregnancy. Lancet Infectious Diseases, The, 2016, 16, 366-375.	4.6	12
71	Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?. European Journal of Neurology, 2021, 28, 2115-2120.	1.7	12
72	Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. Neurology, 2021, 97, e1334-e1342.	1.5	12

#	Article	IF	Citations
73	Combination of Hydroxychloroquine and Indapamide Attenuates Neurodegeneration in Models Relevant to Multiple Sclerosis. Neurotherapeutics, 2021, 18, 387-400.	2.1	12
74	Reproducibility over a 1-month period of 1H-MR spectroscopic imaging NAA/Cr ratios in clinically stable multiple sclerosis patients. European Radiology, 2008, 18, 1736-1740.	2.3	11
75	A fatal demyelinating illness in a young woman 10 weeks post partum. Lancet Neurology, The, 2005, 4, 129-134.	4.9	10
76	Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis. European Journal of Neurology, 2007, 14, 1210-1215.	1.7	9
77	Smoking does not influence disability accumulation in primary progressive multiple sclerosis. European Journal of Neurology, 2017, 24, 624-630.	1.7	8
78	Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis. Journal of Neuroimmunology, 2019, 334, 576974.	1.1	8
79	A comparison of clinical outcomes in PPMS in the INFORMS original trial data set. Multiple Sclerosis Journal, 2021, 27, 1864-1874.	1.4	7
80	Advanced Analysis of Diffusion Tensor Imaging Along With Machine Learning Provides New Sensitive Measures of Tissue Pathology and Intra-Lesion Activity in Multiple Sclerosis. Frontiers in Neuroscience, 2021, 15, 634063.	1.4	7
81	Surgical resection in metastatic spinal cord compression. Lancet, The, 2006, 367, 109.	6.3	6
82	Interferonâ€î² treatment and the natural history of relapsingâ€remitting multiple sclerosis. Annals of Neurology, 2008, 63, 125-126.	2.8	6
83	Treatment of seizures in multiple sclerosis. The Cochrane Library, 2009, , CD007150.	1.5	5
84	MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 561-572.	1.4	5
85	Irreversible Neurological Worsening Following High-Dose Corticosteroids in Advanced Progressive Multiple Sclerosis. Clinical Neuropharmacology, 2006, 29, 18-19.	0.2	4
86	Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset. Journal of Neurology, 2022, 269, 1663-1669.	1.8	4
87	The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. Journal of Neurology, 2022, 269, 5319-5327.	1.8	4
88	Paroxysmal focal dystonia with sensory symptoms secondary to cortical oligoastrocytoma. Journal of Neurology, 2006, 253, 1227-1228.	1.8	3
89	Genetic characterization of measles virus genotype D6 subacute sclerosing panencephalitis case, Alberta, Canada. Journal of NeuroVirology, 2018, 24, 720-729.	1.0	2
90	An enrichment strategy for clinical trials in SPMS. Multiple Sclerosis Journal, 2021, 27, 1884-1893.	1.4	2

#	Article	IF	Citations
91	Multiple Sclerosis Diagnostic Criteria. Neurology, 2022, 98, 12-13.	1.5	2
92	Primary and secondary progressive MS have a similar age at onset of progression â€“ Commentary. Multiple Sclerosis Journal, 2017, 23, 642-643.	1.4	1
93	Serum HGF and APN2 are associated with disability worsening in SPMS. Journal of Neuroimmunology, 2022, 364, 577803.	1.1	1
94	Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS. Multiple Sclerosis Journal, 2021, , 135245852110636.	1.4	1
95	Early firstâ€line treatment response and subsequent disability worsening in relapsingâ€“remitting multiple sclerosis. European Journal of Neurology, 2022, 29, 1106-1116.	1.7	1
96	Reply: Hyperglycaemia and the outcome of stroke. Brain, 2007, 130, e86-e86.	3.7	0
97	CSF oligoclonal bands and progression of disability in multiple sclerosis. European Journal of Neurology, 2008, 15, e24-e24.	1.7	0
98	Epidemiology and Natural History of Multiple Sclerosis. , 2018, , .		0
99	Clinical Reasoning: A pregnant woman with chin numbness. Neurology, 2019, 92, e996-e999.	1.5	0